Ketamine, Psychedelics, and Psychotherapy: Reframing, Redefining, Renaming Treatment Models.

Area of Science:

• Psychiatry
• Pharmacology
• Psychotherapy Research

Background:

• Renewed interest in psychedelic and ketamine therapies for psychiatric disorders like PTSD, MDD, and GAD.
• Proliferation of ketamine treatment clinics necessitates clearer understanding of therapeutic models.
• Current research lacks standardized definitions for psychotherapeutic interventions within psychedelic/ketamine-assisted treatments.

Purpose of the Study:

• To address the lack of standardized definitions in psychedelic and ketamine-based therapies.
• To propose new terminology to differentiate therapeutic roles of agents and psychotherapy.
• To facilitate clearer study designs, regulatory pathways, and informed patient care.

Main Methods:

• Review and discussion of existing psychedelic and ketamine treatment models and methodologies.
• Proposal of three distinct definitions for therapeutic contexts.
• Suggestion of specific language to distinguish between drug-centric, drug-assisted, and psychotherapy-centric approaches.

Main Results:

• Identified confusion regarding the distinct roles of pharmacologic effects versus psychotherapy.
• Proposed definitions to differentiate: (1) drug as stand-alone treatment, (2) drug assisting psychotherapy, and (3) structured psychotherapy with or without drug.
• Highlighted the need for clarity in research and clinical application.

Conclusions:

• Clearer definitions are crucial for evaluating psychedelic and ketamine therapies.
• Proposed terminology can distinguish the therapeutic contributions of agents and psychotherapies.
• Standardized language will advance research rigor, regulatory clarity, and patient outcomes.